Clinical Trial

Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Study acronym: PRCC-MO
Recruiting
View on ClinicalTrials.gov →
Summary
Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.
Trial Details
NCT Number NCT07519837
Lead Sponsor China Medical University, China
Conditions Cachexia; Cancer; Sarcopenia
Enrollment 1,000 participants
Start Date 2026-03-18
Primary Completion 2028-03-20 (estimated)
Study Completion 2028-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-09